Leadership Team

l3e2j-95s7wvz_beauparlantp_02-web

Pierre Beauparlant, Ph.D.

Chief Business Officer

Pierre Beauparlant has more than 19 years of experience in large pharma and development stage, venture backed biopharmaceutical companies with expertise from discovery through commercialization.  As Chief Business Officer, Dr. Beauparlant is responsible for the development and execution of business strategy for Diazon.

Dr. Beauparlant most recently served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Pierre oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities.

Prior to Novartis, Dr. Beauparlant held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property. Dr. Beauparlant is also Chief Business Officer at Therillia.

Dr. Beauparlant holds a Ph.D. from McGill University.

Michael Dixon

Michael Dixon, CPA, CA

Interim President and CFO

Michael Dixon, has over 18 years’ experience working in an executive role for venture-backed companies.

Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada.

Prior to Gemin X, Mr. Dixon was Interim COO and Vice President Finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening.  Mr. Dixon is also president and chief executive officer at Therillia Development Company.

Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.

louise-prouix

Louise Proulx, Ph.D.

Chief Development Officer

Louise Proulx is an industry veteran with 30 years’ experience in the pharmaceutical industry and has held scientific and managerial positions of increasing responsibilities.  Notably, Dr. Proulx was Vice President, Scientific Affairs at Hoechst Marion Roussel Canada, Vice President, Therapeutic Product Development at BioChem Pharma Inc., Vice President, Business Development of Genome Quebec and Vice Principal Research at McGill University. She has been Vice President, Product Development at ViroChem Pharma Inc. and Vice-President, and Site Head, at Vertex Pharmaceuticals (Canada) Incorporated after the acquisition of ViroChem Pharma by Vertex Pharmaceuticals.  Dr. Proulx is also chief development officer at Therillia Development Company.

Dr. Proulx has been a member of several boards of directors and is a member of the board of directors of the Research Institute of McGill University Health Center, Gestion Univalor, Verlyx Pharma and CQDM. Dr. Proulx is certified ICD.D by the Institute of Corporate Directors. She is also member of the Canada Foundation for Innovation.

Dr. Proulx holds a Ph.D. in physiology from Université Laval and pursued postdoctoral studies at the Karolinska Institute in Stockholm.